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Abstract
Growth factors (GFs) are naturally occurring proteins or steroid hormones which act as signaling molecules between cells that
play a key role in the processes of proliferation, cell differentiation and maturation of a wide variety of cells and tissues. A recently
purified synthetic basic b-FGF was assessed using a routine tissue culture assay via  application of a wide range of doses ranged
between 0.1 and 300 ng/mL of the basic fibroblast growth factor (b-FGF) in phosphate buffer saline (PBS) and 10% fetal calf serum
(FCS) on the growth rate of Rama-27  mammary cell line. Applying SPSS “Student T-test” biostatistics the result showed significant
increase (p  ≤  0.05), almost 7 folds in tissue proliferation at a low dose of 0.3 ng/mL FGF in comparison with control tissue (PBS)
only. It is concluded that 0.3 ng/mL dose represents the lower optimal dose suggesting its possibility of an in  vivo  technique to test
its potency in curing skin wounds in rats.
© 2012 Taibah University. Production and hosting by Elsevier B.V. All rights reserved.Keywords: In vitro; Rama-27; Synthetic FGF; Tissue culture
1.  Introduction
All living cells are characterized by their ability to
replicate or go through cell-division, during which the
cell duplicate its DNA and the mitosis phase follows by
the cell splitting itself into two distinct cells, often called
“daughter cells” [8,9,37]. Cell division can be detected
by exposing the cells to radioactively labeled nucleotide
precursors which helps to observe and measure these∗ Corresponding author. Tel.: +966 566848455; fax: +966 48454770.
E-mail address: ayoubbazzaz@yahoo.co.uk (A.A. Bazzaz).
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http://dx.doi.org/10.1016/j.jtusci.2012.10.003“landmark” events providing the basis for defining the
kinetic and regulatory properties of the cell cycle. A
longitudinal observation of a population of cells grown
outside the normal habitat of the body e.g.  in culture, can
most easily be studied within the laboratories under rel-
atively controlled conditions [13]. Cells depending upon
the environmental stimuli established within laboratories
using tissue culture techniques can retain their ability to
divide further in a process called “quiescence” which is
a reversible phenomenon [2,6,26,30]. It also can reveal
basic information about cells and to investigate funda-
mental processes of growth and development in both
normal and abnormal tissues.
Continuous works in tissue culture field have
approved that a mixture of nutrient to ‘add back’ ingre-
dient until an optimal mixture for cell proliferation is
obtained is a step to environment of cells within the
body. This approach converges on the identification of a
core set of molecules required for the survival and most
importantly proliferation of mammalian cells in culture,
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nown as growth factors [3,4]. The mammary cell line
f rats (Rama-27) isolated and grown under excellent
ritical environmental conditions was used to assess the
otential of the basic fibroblast growth factor (b-FGF)
nd to optimize the right dose of it as in  vitro  for future
se as in  vivo  for wound healing.
Growth factors (GFs) are proteins or steroid hor-
ones [39] which are important for regulating a variety
f cellular processes and they typically act as signaling
olecules between cells. In normal tissue, b-FGF is
resent in basement membranes and in the suben-
othelial extracellular matrix of blood vessels. It stays
embrane-bound as long as there is no signal peptide
16,25]. A single GF could be used in assays to assess
ts potency in promoting growth of certain cell line as
n vitro. Application of synthesized GFs is one of the
ays being utilized as a way to maintain skin’s youth.
hey increase the rate at which cells in the body grow,
lay roles in cell division, new cell and blood vessel
rowth, collagen and elastin production and distribution
34]. GFs exert their effect on cells through cell-surface
eceptors, and may bind to one or several receptors. In
ormal tissue, the b-FGF is present in basement mem-
ranes and in the sub-endothelial extracellular matrix of
lood vessels while it stays membrane-bound as long as
here is no signal peptide.
The FGFs are a family of GFs involved in angiogen-
sis, wound healing, and embryonic development. They
re heparin-binding proteins and interactions with cell-
urface associated heparan sulfate proteoglycans have
een shown to be essential for FGF signal transduc-
ion and as key players in the processes of proliferation
nd differentiation of wide variety of cells and tis-
ues. A novel chemical-defined medium with b-FGF and
2B27 supplements supports undifferentiated growth in
uman embryonic stem cells [20]; and interacts with
ree ribosomal protein S19 [31] while intracellular asso-
iation of b-FGF is found with the ribosomal protein
6/TAXREB107 [28]. It can bind to protein kinase CK2
orrelates with mitogenicity [29].
Synthetic GFs are polypeptide that can mimic the
ole of the natural GFs in  vitro  experiments. They are
 specific subgroup of cytokines whose main activity
s the induction of mitosis. They are secreted by a
ide range of cells including macrophages, fibroblasts,
ndothelial cells, and platelets [22,27] and may bind
o one or several receptors. They contribute to blood
essel growth, collagen and elastin production and
istribution [4,22,27–29,36]. GFs also influence and
egulate the degradation and formation of collagen
7,10,11,14,17,18,20,21,24,26,32,38] also exert a
itogenic effect on mesodermal cells, manifestedersity for Science 6 (2012) 28–33 29
as stimulated angiogenesis and granulation tissue
formation [35].
The aim of the present work was designed to optimize
the dose of b-FGF that produces the highest cell growth
in vitro  by using mammary gland cells Rama-27 cell
line. It has been assumed that its role in interacting with
certain cell membrane receptors to provide nutrients to
the germinating cells; act as catalyst to accelerate the cell
growth.
The b-FGF has been synthesized, its chemical struc-
tures and purity being determined at Biochemistry
Department, Liverpool University, UK by professor
David Fernig  who reserves the right for disclosing its
chemical components. Rama-27 from passages 31st of
a rat mammary cell line used in the present study has
been derived from the fast sticking fraction of cells. They
have been isolated from a normal rat mammary gland
and defined as fibroblast on the basis of its ability to
differentiate to the adipocyte phenotype [26].
2. Materials  and  methods
2.1.  Dose  preparations
An amount of basic stock of 20 L b-FGF
(0.33 mg/mL b-FGF dissolved in 1000 L phosphate
buffer saline [PBS], 2 M NaCl, 20 mM phosphate buffer
[PB], 1 mM DTT, pH 6.8) was provided as a stock
solution to prepare working doses. Four sub-stocks (i.e.
5 ng/mL; 100 ng/mL; 1000 ng/mL and 10,000 ng/mL)
were prepared from the basic stock. The final doses (0.01;
0.03; 0.1; 0.3; 1.0; 3.0; 10.0; 100.0 and 300.0 ng/mL)
were then diluted from the above sub-stocks. The equa-
tion of (N1 ×  V1 = N2 ×  V2) has applied for dilution and
preparation of the doses. All doses were prepared of
500 L as working volume.
2.2.  The  Rama-27  cell  line
The Rama-27 cell line has been cultured in Dul-
becco’s Modification of Eagle Medium (DMEM)
[Gibco] supplemented with 5% fetal calf serum (FCS),
50 ng/mL hydrocortisone [Sigma]. These cell lines were
collected from the Tissue bank of the department kept
at −140 ◦C for long-term storage. Rama-27 cells were
kept sparse during the culture because high-density cells
do not synchronize readily. The pH was always kept
checked because they could easily change when adding
3GFs and [ H]-thymidine as DNA synthesis is somewhat
dependent on bicarbonate. Eight plates were used a time
to pool an appropriate amount of confluent cells to use
in these plates. Each sample was tested in triplicate and
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Table 1
The arithmetic mean cell per minute (CPM) and standard deviation (±sd) of Rama-27 cell line counted at different doses of b-FGF (0.01–300 ng/mL).
Note the maximum growth is achieved at 3 different doses ranged between 0.3 and 3.0 ng/mL. (NS) Insignificant (p > 0.05); significant (p ≤ 0.05);
triplicate readings were done for six experiments (total 18 readings). Biostatistics analysis was done using SPSS software.
Parameters Mean ± std. deviation Differences vs SDM Difference vs 10% FCS
Negative control (SDM/BSA) 221 ± 12 – –
Positive control (10% FCS) 457 ± 65 – –
0.01 ng/mL b-FGF 369 ± 94 p ≤ 0.05 NS
0.03 ng/mL b-FGF 458 ± 69 p ≤ 0.05 NS
0.1 ng/mL b-FGF 675 ± 203 p < 0.05 p < 0.05
0.3 ng/mL b-FGF 1682 ± 212 p < 0.05 p < 0.05
1.0 ng/mL b-FGF 1339 ± 322 p < 0.05 p < 0.05
3.0 ng/mL b-FGF 1289 ± 241 p < 0.05 p < 0.05
10 ng/mL b-FGF 404 ± 45 p < 0.05 NS
100 ng/mL b-FGF 399 ± 83 
300 ng/mL b-FGF 356 ± 76 
have included a negative and a positive control (SDM
and 5% FCS respectively) on each plate. Equal volume of
50 L was used in all experiments. Medium is aspirated
from the cells, which were then washed twice with PBS.
1 mL trypsin–EDTA solution was added and incubated
for 5–6 min.
2.3.  Procedure  details  of  the  experiments
In day 1, two plastic Petri dish plates of 80% conflu-
ent cells were trypsinized, cells were suspend in 10 mL
RM, counted using Coulter counter and the suspension
was diluted with RM to give between 30,000 and 40,000
cells per mL. 500 L of cell suspension was pipetted into
each well of the assay plate (to make between 15,000
and 20,000 cells/well) followed by incubation for 24 h at
37 ◦C in a moist oven in 5% CO2. In day 2, the wells
were washed twice with 500 L of PBS, replaced with
500 L SDM and incubated for 24 h at 37 ◦C in a moist
oven in 5% CO2. In day 3, 50 L of cell suspension was
added to the wells and incubated for 18 h at 37 ◦C in a
moist oven in 5% CO2.
In day 4, 20 L of 40 Ci/mL [3H]-thymidine was
added to each well and incubated for 1 h at 37 ◦C inside
oven followed by washing twice with PBS. An amount of
500 L of ice-cold TCA was added and left (15–30 min)
in cold room. Replaced with another 500 L TCA and
removed immediately then washed twice with 500 L of
ice-cold ethanol. The plates were left to dry on top of hot
oven for 15 min. 500 L of 0.2 M NaOH was added to
each well and incubated for 1 h at 37 ◦C in a moist oven
in 5% CO2. Only 300 L of cell suspension was added
to 1 mL of Optiphase scintillation fluid in a scintilla-
tion vial and counted for 10 min in scintillation counter.
Always both positive and negative controls were used
in all experiments and growth activity was recorded asp ≤ 0.05 NS
p ≤ 0.05 NS
the mean count/minute (CPM) with standard deviation
(±sd). The results were expressed as a fold activity of
the negative control or as a percentage of the positive
control.
3. Results
3.1.  Growth  activity  records
Results in Table 1 and Fig. 1 refer to three high-
est records of growth density of Rama-27 cell line as
mean cell per count (CPM) recorded at 3 different doses
of b-FGF (0.3, 0.1 and 3.0 ng/mL). Significant differ-
ences (p  ≤  0.05) in the growth at different doses were
detected in comparison with both negative (step-down
media SDM/bovine serum albumin) and positive control
(10% fetal calf serum {FCS}). The rate of growth indi-
cates a regular ascending pattern with the increased dose
in vitro  up to 0.3 ng/mL. The highest record of Rama-27
cell line growth activity was at 0.3 ng/mL that repre-
sents almost 7 folds of the negative control and around
3–4 folds of the positive control. The growth rate, how-
ever, revealed a descending pattern beyond 1.0 ng/mL
indicating the threshold ranges of the b-FGF doses.
4. Discussion
Many natural GFs e.g.  insulin-like growth factor
(IGF) and epidermal growth factor (EGF) do exist in
various mammalian fresh milk i.e.  human, mouse, rat
and swine which all have growth promoting activity
regarding growth of cells both in  vitro  and in  vivo
[13,19]. Any milk, once boiled, the growth factors will
be disabled due to the de-naturalization of amino acid
components of the GFs. Bovine milk contains a major
growth-promoting activity for rat mammary fibroblast
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Fig. 1. Effects of growth promoting activity of b-FGF is notable on proliferation of Rama-27 cell line by over confluent treated with b-FGF in
comparison with positive control (10% FCS) at both 9 and 18 h. (A) 10% confluent after 9 h with 10% FCS only; (B) 90% confluent after 9 h
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wreatment with 0.3 ng/mL FGF; (C) 50% confluent after 18 h with 10%
100×).
ell line (Rama-27) which is structurally different than
ther GFs [3,4,13]. Due to the fear of some unexpected
erms i.e.  virus being carried on and transmitted to
uman being via  naturally produced products which have
rowth promoting activity, attention has been given to
roduce synthetic peptides on industrial scales to mimic
he action of these growth hormones [3,6]. The synthetic
Fs alone had a little or no significant effects on growth
f Rama-27 cell line unless with Natural  Standard  Prod-
ct (NSP) [3]. No additives of the NSP were added to the
-FGF in these experiments as the target was to assess
olely its activity. It therefore is likely that the mixture of
he present synthesized b-FGF with NSP could produce
etter outcome; however, this was out of scope of this
tudy. It is therefore recommended to carry out further
xperiments to check the activity of the current b-FGF
ogether with the NSP in future. The results showed
ignificantly higher activity of b-FGF on its own than
ur previous works [3,4]. They may therefore indicate a
elative improvement into the synthesis, preparation pro-
edure and purity of GFs in comparison with the previous
orks.nly and (D) 180% confluent after 18 h treatment with 0.3 ng/mL FGF
The mechanism of action of this b-FGF molecules
has not been the scope of this study to investigate but it is
likely that it exerted its effect on these cells through the
cell-surface receptors via  binding to one or more recep-
tors to induce cell proliferation [1,5,12,15,28,31,33].
Further investigation using molecular biology
techniques is recommended which is out of scope
of the present in  vitro  study.
Naturally, every cell does contain a trace of GF while
with the addition of 0.3 ng/mL of b-FGF it triggered a
rapid proliferation in a shorter time. The dose 0.3 ng/mL
had produced the highest cell proliferation among other
doses. It is not wrong to assume that 0.3 ng/mL dose
is an optimal dose which provided enough nutrients
needed to the cells and acted as catalyst to speed up
cell division. In other words, it is not wrong to con-
clude that such a low dose might solely be specific to
b-FGF whereas other GF might vary in their optimal
doses. That would also depend upon other factors i.e.
the structure and components of the GF itself, mecha-
nism of action, temperature, pHs, etc. [23]. The b-FGF
has proved its compatibility to work on Rama-27 cells
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to accelerate their division in  vitro. The 0.3 ng/mL b-
FGF has provided the least workable dose to produce
the highest number of cell and indicated as a threshold
dose. Therefore it represents the optimal dose for rat
tissues.
Our next intension would be to assess the potency of
the above optimal dose of the synthetic b-FGF in curing
skin healing wounds by topical application on injured
skin of rats.
5. Conclusion
The new synthesized b-FGF used as in  vitro  in this
work, without NSP, has proved to be potential in activat-
ing the cell division in Rama-27 cell cultures at a dose
(0.3 ng/mL in PB). The latter might represent an ideal
dose candidate in pharmaceutical uses for medical pur-
poses i.e.  “in  vivo” applications with other medications
at surgical operations to speed up the process of skin
healing and perhaps as a juvenile hormone (skin care) as
an anti-wrinkle agent.
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